![Geoffrey E. Clark](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Geoffrey E.
Clark is currently the Chairman at Ischemix, Inc. He was formerly the Chief Medical Officer at Citius Pharmaceuticals, Inc.
Actieve functies van Geoffrey E. Clark
Bedrijven | Functie | Begin |
---|---|---|
Ischemix, Inc.
![]() Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Voorzitter | - |
Eerdere bekende functies van Geoffrey E. Clark
Bedrijven | Functie | Einde |
---|---|---|
CITIUS PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 12-09-2014 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
CITIUS PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Ischemix, Inc.
![]() Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |